<DOC>
	<DOC>NCT01257386</DOC>
	<brief_summary>To demonstrate that import Mesalazine (AsacolÂ®) is non-inferior to the reference drug, marketed Mesalazine, regarding the primary endpoint (reduction of UC-DAI score)in patients with active ulcerative colitis (UC) treated for 8 weeks.</brief_summary>
	<brief_title>Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Patients with Ulcerative Colitis (UC) at active phase who are defined to show Ulcerative ColitisDisease Activitiy Index (UCDAI) score of 3 or higher but 8 or less, and bloody stool score of 1 or higher Patients with serious or higher according to diagnostic critera of seriousness and patients with chronic persistent type and with acute serious type in the classification by clinical course</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>